Kezar Life Sciences, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical crossroads, having stripped away everything but its most promising asset, zetomipzomib. The successful elimination of debt and the narrowing of losses demonstrate a disciplined approach to capital preservation, but the fundamental challenge remains the high cost of clinical success. The alignment with the FDA on the AIH trial design provides a concrete catalyst, yet the looming milestone payments to Onyx and the lack of internal revenue create a high-stakes environment. Ultimately, Kezar is no longer operating as a traditional biotech developer but as a strategic asset for sale. The focus on 'strategic alternatives' suggests that management is seeking a partner or acquirer to provide the capital and infrastructure necessary for commercialization. Investors are now weighing the potential for a high-value buyout against the risk of a liquidity crunch if a deal does not materialize before the current cash runway expires in 2027.